Vasopressin to Control Blood Loss during Hysterectomy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

What It Covers

The paper reports a study of Vasopressin, published as a meta-analysis.

Minimizing intraoperative blood loss during hysterectomy is crucial to lessen associated perioperative morbidity.

The aim of this investigation is to conduct a systematic review and meta-analysis of all randomized controlled trials (RCTs) that compared vasopressin versus normal saline in controlling intraoperative blood loss during hysterectomy.

Why It Was Studied

The researchers screened 5 major databases (PubMed, Scopus, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials) from inception till July 18, 2021.

The researchers used the following query search in all databases: (vasopressin OR arginine vasopressin OR argipressin OR antidiuretic hormone) AND (hysterectomy) AND (saline OR placebo OR control OR no treatment) AND (randomized OR randomised OR randomly).

Who the Included Studies Covered

PubMed tags the participants as women only.

The researchers considered all studies that met the following evidence-based criteria: (1) patients: individuals undergoing hysterectomy for any indication, (2) intervention: vasopressin, (3) comparator: normal saline, placebo, or no treatment, (4) outcomes: reliable extraction of any of their endpoints, and (5) study design: RCTs.

How the Review Was Done

The researchers performed statistical analysis using the Review Manager software, version 5.4.0.

What Was Measured

PubMed files the paper under topics including Blood Loss, Surgical, Hysterectomy, Hysterectomy, Vaginal, Randomized Controlled Trials as Topic and Vasopressins.

The authors tagged it with the keywords Bleeding, Blood transfusion, Febrile morbidity, Hemoglobin and Pelvic infection.

What This Means in Plain Language

This is a meta-analysis of Vasopressin.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Journal of minimally invasive gynecology), a journal based in United States.

More context: the Vasopressin compound page, all human trials.